Mycophenolate sodium is enteric coated and has been suggested as a potential method to reduce the gastrointestinal adverse events seen with mycophenolate ...

An enteric coated formulation of mycophenolate sodium (EC MPS; myfortic®) has been developed with the aim of improving the upper GI tolerability of mycophenolic ...

Conversion from MMF to EC-MPS may be associated with improvements in presence and severity of GI symptoms, particularly in patients with indigestion, diabetes, ...

21 июл. 2015 г. · Patients switched to EC-MPS experienced less gastrointestinal symptom burden and showed improvement in HRQoL.

Enteric-coated mycophenolate sodium (EC-MPS) is a formulation of MPA that delivers the same efficacy benefits as MMF, with the potential to reduce the GI ...

Enteric-coated mycophenolate sodium is a novel derivative of MPA formulated in an attempt to overcome the upper GI adverse effects observed in patients taking ...

26 авг. 2010 г. · Areas covered in this review: Enteric-coated mycophenolate sodium (EC-MPS) is designed to improve the gastrointestinal (GI) tolerability of MPA.

13 нояб. 2018 г. · Globally, enteric-coated mycophenolate sodium (EC-MPS) is replacing mycophenolate mofetil (MMF) in maintenance immunosuppressant regimens.

Introduction Mycophenolate sodium, an enteric-coated tablet (EC-MPS), is as effective and safe as mycophenolate mofetil (MMF) in preventing transplant rejection ...